Back to results
US 2017/0049829 A1Published application
Attenuated reovirus
AssigneeVirocure, Inc.
InventorsManbok KIM, Randal N. Johnston
Life of this patent
Estimating the term…
Abstract
Compositions and methods are provided that relate to an attenuated reovirus exhibiting oncolytic activity toward cancer cells while displaying reduced lytic activity toward non-malignant cells. Exemplified is an attenuated human reovirus derived from persistently infected fibrosarcoma cells that lacks wild-type reovirus S1 and S4 genes and consequently lacks a detectable reoviral outer capsid .sigma.1 protein and expresses a mutated reoviral outer capsid .sigma.3 protein.
Claims20
A method of treating an activated oncogene-associated malignant condition, comprising:
- (a) administering an effective amount of an attenuated reovirus to a subject having an activated oncogene-associated malignant condition, under conditions and for a time sufficient for the attenuated reovirus to mediate an oncolytic effect;
- or (b) contacting one or a plurality of malignant cells from a subject having an activated oncogene-associated malignant condition with an effective amount of an attenuated reovirus, under conditions and for a time sufficient for the attenuated reovirus to mediate an oncolytic effect.
Dependencies are inferred from the claim text.